HTR4 and cardiac arrhythmia: Cisapride, a first‐generation 5‐HT4 receptor agonist with low selectivity for 5‐HT4, has demonstrated some efficacy in CIPO [20]; however, it has since been withdrawn because of fatal cardiac arrhythmias and cardiovascular events [30].